By Keith S. Wexler, MBA, CFO, CIO – Maternal Fetal Medicine, Prenatal Diagnosis and Biotech/Life Sciences Consultant, GENASSIST, Inc.
Paul Wexler, M.D., F.A.C.O.G., Medical Director, GENASSIST, Inc.
Clinical Professor, Department of OB/GYN, University of Colorado Health Sciences Center
Clinical Professor, Division of Genetics/Dept. of Pediatrics, Univ. of Colorado/The Children’s Hospital
Hemophilias are medical diseases in which the affected individual has a decreased ability for blood to clot.
Both Hemophilia A and Hemophilia B can be acquired although it is uncommon. X-linked inheritance has been described. 50% of males will be affected, 50% of females will be carriers. *Rarely, carrier females will be affected. If affected, their condition is usually milder.
Acquired Hemophilia A is the most common acquired Hemophilia.
The prevalence of Hemophilia A [deficiency in blood Factor VIII (8) antihemophilioglobulin] is approximately 1 in 5000.
Hemophilia B [deficiency in blood Factor IX (9)] has a prevalence of approximately 1 in 25,000.
Both Hemophilia A and Hemophilia B are inherited in a sex-linked (X-linked) manner, which means that 50% of male children will be affected and 50% of female children will be carriers from a mother who is a carrier and 100% of female children will be carriers and no males affected or carriers from a father with the disease.
Hemophilia C which is uncommon is inherited in an autosomal recessive manner and has a prevalence of approximately 1 in 100,000 with a higher prevalence in patients of Ashkenazi Jewish heritage and is due to a deficiency in blood Factor XI (11).